{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:14:03Z","timestamp":1774005243501,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,7,4]],"date-time":"2008-07-04T00:00:00Z","timestamp":1215129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s10549-008-0020-7","type":"journal-article","created":{"date-parts":[[2008,7,3]],"date-time":"2008-07-03T20:44:59Z","timestamp":1215117899000},"page":"485-493","source":"Crossref","is-referenced-by-count":70,"title":["Analysis of dermatologic events in patients with cancer treated with lapatinib"],"prefix":"10.1007","volume":"114","author":[{"given":"M. E.","family":"Lacouture","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M.","family":"Laabs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. W.","family":"Sweetman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Di Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. L.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. M.","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. M.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. L.","family":"Blackwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,4]]},"reference":[{"key":"20_CR1","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ejca.2005.03.018","volume":"41","author":"AP Dei Tos","year":"2005","unstructured":"Dei Tos AP, Ellis I (2005) Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur J Cancer 41:1383\u20131392","journal-title":"Eur J Cancer"},{"key":"20_CR2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/1097-0142(19940801)74:3<795::AID-CNCR2820740303>3.0.CO;2-I","volume":"74","author":"Y Itakura","year":"1994","unstructured":"Itakura Y, Sasano H, Shiga C et al (1994) Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74:795\u2013804","journal-title":"Cancer"},{"key":"20_CR3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","volume":"55","author":"AL Agero","year":"2006","unstructured":"Agero AL, Dusza SW, Benvenuto-Andrade C et al (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55:657\u2013670","journal-title":"J Am Acad Dermatol"},{"key":"20_CR4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803\u2013812","journal-title":"Nat Rev Cancer"},{"key":"20_CR5","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","volume":"43","author":"AF Galimont-Collen","year":"2007","unstructured":"Galimont-Collen AF, Vos LE, Lavrijsen AP et al (2007) Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 43:845\u2013851","journal-title":"Eur J Cancer"},{"key":"20_CR6","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","volume":"23","author":"R Perez-Soler","year":"2005","unstructured":"Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23:5235\u20135246","journal-title":"J Clin Oncol"},{"issue":"11 suppl 5","key":"20_CR7","first-page":"34","volume":"21","author":"LI Wagner","year":"2007","unstructured":"Wagner LI, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist\u2019s perspective. Oncology 21(11 suppl 5):34\u201336","journal-title":"Oncology"},{"key":"20_CR8","unstructured":"Tykerb [package insert] (2007) GlaxoSmithKline, Research Triangle Park, NC"},{"issue":"suppl","key":"20_CR9","first-page":"266s","volume":"23","author":"AL Fields","year":"2005","unstructured":"Fields AL, Rinaldi DA, Henderson CA et al (2005) An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer [abstract]. J Clin Oncol 23(suppl):266s. Abstract 3583","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"20_CR10","first-page":"645s","volume":"23","author":"HJ Ross","year":"2005","unstructured":"Ross HJ, Blumenschein GR, Dowlati A et al (2005) Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer [abstract]. J Clin Oncol 23(suppl):645s. Abstract 7099","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"20_CR11","first-page":"401s","volume":"23","author":"C Wulfing","year":"2005","unstructured":"Wulfing C, Machiels J, Richel D et al (2005) A single arm, multicenter, open-label, phase II study of lapatinib as 2L treatment of patients with locally advanced\/metastatic transitional cell carcinoma (TCC) of the urothelial tract [abstract]. J Clin Oncol 23(suppl):401s. Abstract 4594","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"20_CR12","first-page":"217s","volume":"24","author":"A Ravaud","year":"2006","unstructured":"Ravaud A, Gardner J, Hawkins R et al (2006) Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 24(suppl):217s. Abstract 4502","journal-title":"J Clin Oncol"},{"key":"20_CR13","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733\u20132743","journal-title":"N Engl J Med"},{"key":"20_CR14","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2165\/00003495-200767140-00008","volume":"67","author":"S Dhillon","year":"2007","unstructured":"Dhillon S, Wagstaff AJ (2007) Lapatinib. Drugs 67:2101\u20132108; discussion 2109\u20132110","journal-title":"Drugs"},{"key":"20_CR15","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1517\/14656566.8.13.2189","volume":"8","author":"A Mukherjee","year":"2007","unstructured":"Mukherjee A, Dhadda AS, Shehata M et al (2007) Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer. Expert Opin Pharmacother 8:2189\u20132204","journal-title":"Expert Opin Pharmacother"},{"key":"20_CR16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1517\/14712598.7.2.257","volume":"7","author":"F Montemurro","year":"2007","unstructured":"Montemurro F, Valabrega G, Aglietta M (2007) Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 7:257\u2013268","journal-title":"Expert Opin Biol Ther"},{"key":"20_CR17","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1200\/JCO.2005.16.584","volume":"23","author":"HA Burris","year":"2005","unstructured":"Burris HA, Hurwitz HI, Dees EC et al (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305\u20135313","journal-title":"J Clin Oncol"},{"key":"20_CR18","unstructured":"Cancer Therapy Evaluation Program (1999) Common toxicity criteria, version 2.0. http:\/\/ctep.cancer.gov\/forms\/CTCv20_4-30-992.pdf . Accessed 7 Feb 2008"},{"key":"20_CR19","unstructured":"Cancer Therapy Evaluation Program (2006) Common terminology criteria for adverse events, version 3.0 (CTCAE). http:\/\/ctep.cancer.gov\/forms\/CTCAEv3.pdf . Accessed 7 Feb 2008"},{"key":"20_CR20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/rcm.1327","volume":"18","author":"S Hsieh","year":"2004","unstructured":"Hsieh S, Tobien T, Koch K et al (2004) Increasing throughput of parallel on-line extraction liquid chromatography\/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development. Rapid Commun Mass Spectrom 18:285\u2013292","journal-title":"Rapid Commun Mass Spectrom"},{"key":"20_CR21","unstructured":"Tarceva [package insert] (2007) OSI Pharmaceuticals Inc, Melville, NY"},{"key":"20_CR22","unstructured":"Nexavar [package insert] (2007) Bayer Pharmaceuticals Corp, West Haven, CT"},{"key":"20_CR23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1634\/theoncologist.12-5-610","volume":"12","author":"TJ Lynch Jr","year":"2007","unstructured":"Lynch TJ Jr, Kim ES, Eaby B et al (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610\u2013621","journal-title":"Oncologist"},{"key":"20_CR24","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-04-1168","volume":"64","author":"ER Wood","year":"2004","unstructured":"Wood ER, Truesdale AT, McDonald OB et al (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64:6652\u20136659","journal-title":"Cancer Res"},{"key":"20_CR25","doi-asserted-by":"crossref","first-page":"9139","DOI":"10.1158\/0008-5472.CAN-04-1036","volume":"64","author":"ML Amador","year":"2004","unstructured":"Amador ML, Oppenheimer D, Perea S et al (2004) An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64:9139\u20139143","journal-title":"Cancer Res"},{"key":"20_CR26","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/1523-1747.ep12874601","volume":"94","author":"LB Nanney","year":"1990","unstructured":"Nanney LB, Stoscheck CM, King LE Jr et al (1990) Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 94:742\u2013748","journal-title":"J Invest Dermatol"},{"key":"20_CR27","first-page":"1","volume":"63","author":"C Kari","year":"2003","unstructured":"Kari C, Chan TO, Rocha de Quadros M et al (2003) Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 63:1\u20135","journal-title":"Cancer Res"},{"key":"20_CR28","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2133.2006.07452.x","volume":"155","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME, Lai SE (2006) The PRIDE (Papulopustules and\/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 155:852\u2013854","journal-title":"Br J Dermatol"},{"key":"20_CR29","unstructured":"Erbitux [package insert] (2007) Imclone Systems Inc, Branchburg, NJ"},{"key":"20_CR30","unstructured":"Vectibix [package insert] (2007) Amgen Inc, Thousand Oaks, CA"},{"key":"20_CR31","unstructured":"Iressa [package insert] (2005) AstraZeneca Pharmaceuticals, Wilmington, DE"},{"key":"20_CR32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2004.06026.x","volume":"151","author":"W Jacot","year":"2004","unstructured":"Jacot W, Bessis D, Jorda E et al (2004) Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 151:238\u2013241","journal-title":"Br J Dermatol"},{"key":"20_CR33","unstructured":"Xeloda [package insert] (2006) Roche Pharmaceuticals, Nutley, NJ"},{"issue":"suppl","key":"20_CR34","first-page":"494s","volume":"25","author":"A Jatoi","year":"2007","unstructured":"Jatoi A, Rowland K, Sloan JA et al (2007) Does tetracycline prevent\/palliate epidermal growth factor receptor (EGFR) inhibitor-induced rash? A phase III trial from the North Central Cancer Treatment Group (N03CB) [abstract]. J Clin Oncol 25(suppl):494s. Abstract LBA9006","journal-title":"J Clin Oncol"},{"key":"20_CR35","first-page":"17","volume":"21","author":"ME Lacouture","year":"2007","unstructured":"Lacouture ME, Cotliar J, Mitchell EP (2007) Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology (Williston Park) 21:17\u201321","journal-title":"Oncology (Williston Park)"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0020-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-008-0020-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0020-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:28:58Z","timestamp":1559233738000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-008-0020-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,4]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["20"],"URL":"https:\/\/doi.org\/10.1007\/s10549-008-0020-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,4]]}}}